文献速递心力衰竭与心肌病

达格列净在DAPA-HF研究中按背景心衰治疗的效应分析

Effects of dapagliflozin in DAPA-HF according to background heart failure therapy.
PubMed 文献 · Eur Heart J · 2020-01-01

该研究为DAPA-HF试验的事后分析,评估达格列净在射血分数降低心衰患者中疗效是否受背景心衰治疗影响。主要复合终点(心血管死亡或心衰恶化事件)总体风险比0.74(95%CI 0.65-0.85,P<0.0001),各亚组间疗效一致,无显著交互作用。

要点

  • 达格列净降低主要复合终点风险,HR 0.74(95%CI 0.65-0.85,P<0.0001)。
  • 无论是否使用利尿剂、地高辛、MRA、沙库巴曲缬沙坦、伊伐布雷定、ICD或CRT,疗效一致。
  • 背景RAS阻滞剂、β受体阻滞剂和MRA剂量水平不影响达格列净的获益。

核心结论

  • 达格列净的获益与心衰背景治疗无关,在各亚组中保持一致。

研究设计与样本

  • DAPA-HF试验的事后分析,纳入4744例随机化患者,按背景心衰治疗(是/否)及药物剂量水平分组。

主要发现

  • 总体主要复合终点HR 0.74(95%CI 0.65-0.85,P<0.0001)。
  • 各亚组HR范围0.57-0.86,无显著治疗-by-亚组交互作用。
  • 基线同时使用RAS阻滞剂、β受体阻滞剂和MRA者HR 0.72(95%CI 0.61-0.86),未同时使用三者者HR 0.77(95%CI 0.63-0.94),P-interaction 0.64。
  • 84%患者使用利尿剂,94%使用RAS阻滞剂,96%使用β受体阻滞剂;52%的β受体阻滞剂使用者和38%的RAS阻滞剂使用者剂量≥推荐剂量的50%。

临床怎么用

  • 达格列净可考虑用于射血分数降低心衰患者,无论其背景心衰治疗如何。

局限性

  • 为事后分析,亚组分析非预设主要分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: In the DAPA-HF trial, the SGLT2 inhibitor dapagliflozin reduced the risk of worsening heart failure (HF) and death in patients with HF and reduced ejection fraction. We examined whether this benefit was consistent in relation to background HF therapy. METHODS AND RESULTS: In this post hoc analysis, we examined the effect of study treatment in the following yes/no subgroups: diuretic, digoxin, mineralocorticoid receptor antagonist (MRA), sacubitril/valsartan, ivabradine, implanted cardioverter-defibrillating (ICD) device, and cardiac resynchronization therapy. We also examined the effect of study drug according to angiotensin-converting enzyme inhibitor/angiotensin receptor blocker dose, beta-blocker (BB) dose, and MRA (≥50% and <50% of target dose). We analysed the primary composite endpoint of cardiovascular death or a worsening HF event. Most randomized patients (n = 4744) were treated with a diuretic (84%), renin-angiotensin system (RAS) blocker (94%), and BB (96%); 52% of those taking a BB and 38% taking a RAS blocker were treated with ≥50% of the recommended dose. Overall, the dapagliflozin vs. placebo hazard ratio (HR) was 0.74 [95% confidence interval (CI) 0.65-0.85] for the primary composite endpoint (P < 0.0001). The effect of dapagliflozin was consistent across all subgroups examined: the HR ranged from 0.57 to 0.86 for primary endpoint, with no significant randomized treatment-by-subgroup interaction. For example, the HR in patients taking a RAS blocker, BB, and MRA at baseline was 0.72 (95% CI 0.61-0.86) compared with 0.77 (95% CI 0.63-0.94) in those not on all three of these treatments (P-interaction 0.64). CONCLUSION: The benefit of dapagliflozin was consistent regardless of background therapy for HF.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Docherty KF, Jhund PS, Inzucchi SE, et al. Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. Eur Heart J. 2020. PMID: 32221582. doi:10.1093/eurheartj/ehaa183

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。